Table 1.
Covariate comparison between groups before and after propensity score matching.
| Variable | Participants (n = 455) | Non-participants (n = 1625) | P-value | Std mean diff | Intervention (n = 452) | Matched control group (n = 1500) | P-value | Std mean diff |
|---|---|---|---|---|---|---|---|---|
| Demographics | ||||||||
| Age | 53 | 52.7 | 0.644 | 0.21 | 52.9 | 52.9 | 0.85 | 0.01 |
| Sex | ||||||||
| Male | 26.6% | 24.7% | 0.46 | 0.02 | 26.3% | 25.8% | 0.53 | 0.01 |
| Female | 73.4% | 75.3% | 0.04 | 73.7% | 74.0% | 0.01 | ||
| Zip code region (0–9) | ||||||||
| 0 | 10.6% | 10.3% | 0.56 | 0.01 | 10.4% | 10.6% | 0.89 | 0.01 |
| 1 | 7.5% | 9.0% | 0.06 | 7.5% | 7.7% | 0.01 | ||
| 2 | 13.6% | 11.3% | 0.07 | 13.7% | 13.6% | 0.00 | ||
| 3 | 17.4% | 18.7% | 0.03 | 17.5% | 17.6% | 0.00 | ||
| 4 | 10.3% | 8.0% | 0.08 | 10.2% | 10.5% | 0.01 | ||
| 5 | 1.0% | 1.0% | 0.01 | 1.0% | 1.0% | 0.01 | ||
| 6 | 10.6% | 12.1% | 0.05 | 10.6% | 10.8% | 0.01 | ||
| 7 | 15.6% | 17.4% | 0.05 | 15.7% | 15.2% | 0.01 | ||
| 8 | 5.3% | 4.1% | 0.05 | 5.1% | 5.0% | 0.01 | ||
| 9 | 8.6% | 8.4% | 0.01 | 8.6% | 8.3% | 0.01 | ||
| Risk Factors | ||||||||
| Number of meds | 12.7 | 12.3 | 0.28 | 0.06 | 12.6 | 12.6 | 0.43 | 0.00 |
| Number of PGx meds | 4.3 | 4 | 0.04 | 0.11 | 4.2 | 4.2 | 0.14 | 0.00 |
| Baseline medical cost (PMPM) | 1515.85 | 2117.47 | 0.03 | 0.18 | 1501.43 | 1558.62 | 0.87 | 0.02 |
| CCI | 1.5 | 1.6 | 0.68 | 0.02 | 1.5 | 1.6 | 0.63 | 0.02 |
CCI Charlson Comorbidity Index, PMPM per member per month, PGx Pharmacogenomics.